Study Shows Potential for New Glioblastoma Treatment
A completely new treatment for glioblastoma, which combines a common chemotherapy agent with T cells, may enter clinical trials following highly successful mouse-model studies. Researchers with the Jonsson Comprehensive Cancer Center at the University of California, Los Angeles reported in the journal Neuro-Oncology that this new hybrid treatment has successfully passed all animal studies and is being considered for clinical trials in humans due to its apparent lower risks combined with improved outcomes. The treatment is recommended for fast-growing tumors following surgery in order to prevent the highly common relapses found following glioblastoma removals. “By treating glioblastoma cells with decitabine, we found that we can unmask targets on the tumor cell that can be recognized by killer T cells,” he adds. “Once these targets are uncovered, we can then administer T cells that are genetically programmed to attack tumor cells with the new targets.” To learn more about this study, click here.
2017 AANS/CNS Section on Pediatric Neurological Surgery
Nov. 28-Dec. 1, 2017; Houston
2nd Homburg ICP and Hydrocephalus Workshop
Nov. 28-30, 2017; Germany
22nd Instructional Course and 45th Annual Meeting of the Cervical Spine Research Society
Nov. 29, 2017 - Dec. 2, 2017; Hollywood, Fla.